# CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

> **NCT03605927** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 45 (actual)

## Conditions studied

- Graft-versus-host-disease
- GVHD
- GVHD, Acute

## Interventions

- **DRUG:** BMS-986004
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT03605927
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605927, "CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03605927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*